Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Harvard Bioscience Inc’s current trading price is -83.38% away from its 52-week high, while its distance from the 52-week low is 93.21%. The stock’s price range over this period has fluctuated between $0.28 and $3.27. The company, operating within the financial sector, had a trading volume of approximately 1.5 million for the day, which was noticeably lower than the average daily share volume of 11.92 million over the last 3 months.
At present, Harvard Bioscience Inc (HBIO) has a stock price of $0.54. In the previous session, the stock saw a rise, peaking at $3.0 after an opening price of $0.54. The day’s lowest price was $3.0, and it closed at $0.5.
Harvard Bioscience Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $3.27 on 08/27/24 and a low of $0.28 for the same time frame on 05/28/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Harvard Bioscience Inc (HBIO) has experienced a quarterly rise of 45.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 24.20M and boasts a workforce of 355 employees.
Harvard Bioscience Inc: What Analysts Are Saying
As of right now, 1 analyst is rating Harvard Bioscience Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.4392, with a change in price of -0.0447. Similarly, Harvard Bioscience Inc recorded 7,811,831 in trading volume during the last 100 days, posting a change of -7.60%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for HBIO stands at 2.75. Similarly, the long-term debt-to-equity ratio is also 0.45.
HBIO Stock Stochastic Average
Today, Harvard Bioscience Inc’s raw stochastic average for the past 50 days stands at 62.02%, indicating a decline from the raw stochastic average of the last 20 days, which was 82.33%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 64.60% and 49.38% respectively.
HBIO Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a loss of -80.86%.However, over the last six months, we can see a stronger performance of -37.52%. Over the last 30 days, the price of HBIO has fallen by 2.70%. And in the last five days, it has surged by 11.60%.
